Lily Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lily Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Tanya M. Laidlaw
Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass
5 shared publicationsElena Losina
Harvard Medical School, Boston, Mass; Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Mass
3 shared publicationsKaren H. Costenbader
Harvard Medical School, Boston, Mass; Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
3 shared publicationsYuchiao Chang
Harvard Medical School, Boston, Mass; Division of General Internal Medicine, Massachusetts General Hospital, Boston, Mass
3 shared publicationsJillian Bensko
Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
2 shared publicationsAntonia F. Chen
Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, Mass; Department of Orthopedic Surgery, Harvard Medical School, Boston, Mass
1 shared publication
Latest Publications
- 2 October 2024
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 155 (1) , 84-86
Role of anti-IgE in immediate drug allergy
- 2 October 2024
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 155 (1) , 84-86
Role of anti-IgE in immediate drug allergy
- 30 November 2023
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 153 (3) , 772-779.e4
Nonsteroidal anti-inflammatory drug “allergy” labeling is associated with increased postpartum opioid utilization
- 30 November 2023
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 153 (3) , 772-779.e4
Nonsteroidal anti-inflammatory drug “allergy” labeling is associated with increased postpartum opioid utilization
- 9 November 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 131 (5) , S16
NSAID ALLERGY LABELING AND POSTPARTUM OPIOID UTILIZATION FOLLOWING VAGINAL OR CESAREAN DELIVERY
- 9 November 2023
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 131 (5) , S16
NSAID ALLERGY LABELING AND POSTPARTUM OPIOID UTILIZATION FOLLOWING VAGINAL OR CESAREAN DELIVERY
- 21 March 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (6) , 1891-1898.e3
Association of Reported Nonsteroidal Anti-Inflammatory Drug (NSAID) Adverse Drug Reactions With Opioid Prescribing After Total Joint Arthroplasty
- 21 March 2023
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (6) , 1891-1898.e3
Association of Reported Nonsteroidal Anti-Inflammatory Drug (NSAID) Adverse Drug Reactions With Opioid Prescribing After Total Joint Arthroplasty
- 22 December 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (2) , 652-654
Two-step nonsteroidal anti-inflammatory drug challenges during pregnancy: A case series
- 22 December 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (2) , 652-654
Two-step nonsteroidal anti-inflammatory drug challenges during pregnancy: A case series
- 25 February 2022
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 128 (5) , 602-603
Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020
- 25 February 2022
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 128 (5) , 602-603
Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020
- 17 November 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (5) , 1286-1292.e2
Safety, Outcomes, and Recommendations for Two-Step Outpatient Nonsteroidal Anti-Inflammatory Drug Challenges
- 17 November 2021
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 10 (5) , 1286-1292.e2
Safety, Outcomes, and Recommendations for Two-Step Outpatient Nonsteroidal Anti-Inflammatory Drug Challenges
- 1 April 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (4) , 433-435
Reported drug allergies among patients with opioid use disorder
- 1 April 2021
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 126 (4) , 433-435
Reported drug allergies among patients with opioid use disorder
- 9 September 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (4) , 1413-1419
Impact of reported NSAID “allergies” on opioid use disorder in back pain
- 9 September 2020
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (4) , 1413-1419
Impact of reported NSAID “allergies” on opioid use disorder in back pain
- Open Access
- 7 August 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (8) , e1003247
Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study
Patients with opioid use disorder (OUD) who are hospitalized for serious infections requiring prolonged intravenous antibiotics may face barriers to discharge, which could prolong hospital length of stay (LOS) and increase financial burden. We investigated differences in LOS, discharge disposition, and charges between hospitalizations for serious infections in patients with and without OUD. We utilized the 2016 National Inpatient Sample—a nationally representative database of all discharges from US acute care hospitals. The population of interest was all hospitalizations for infective endocarditis, epidural abscess, septic arthritis, or osteomyelitis. The exposure was OUD, and the primary outcome was LOS until discharge, assessed by using a competing risks analysis to estimate adjusted hazard ratios (aHRs). Adjusted odds ratio (aOR) of discharge disposition and adjusted differences in hospital charges were also reported. Of 95,470 estimated hospitalizations for serious infections (infective endocarditis, epidural abscess, septic arthritis, and osteomyelitis), the mean age was 49 years and 35% were female. 46% had Medicare (government-based insurance coverage for people age 65+ years), and 70% were non-Hispanic white. After adjustment for potential confounders, OUD was associated with a lower probability of discharge at any given LOS (aHR 0.61; 95% CI 0.59–0.63; p < 0.001). OUD was also associated with lower odds of discharge to home (aOR 0.38; 95% CI 0.33–0.43; p < 0.001) and higher odds of discharge to a post-acute care facility (aOR 1.85; 95% CI 1.57–2.17; p < 0.001) or patient-directed discharge (also referred to as “discharge against medical advice”) (aOR 3.47; 95% CI 2.80–4.29; p < 0.001). There was no significant difference in average total hospital charges, though daily hospital charges were significantly lower for patients with OUD. Limitations include the potential for unmeasured confounders and the use of billing codes to identify cohorts. Our findings suggest that among hospitalizations for some serious infections, those involving patients with OUD were associated with longer LOS, higher odds of discharge to post-acute care facilities or patient-directed discharge, and similar total hospital charges, despite lower daily charges. These findings highlight opportunities to improve care for patients with OUD hospitalized with serious infections, and to reduce the growing associated costs.
- 7 August 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (8) , e1003247
Open AccessDisparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study
Patients with opioid use disorder (OUD) who are hospitalized for serious infections requiring prolonged intravenous antibiotics may face barriers to discharge, which could prolong hospital length of stay (LOS) and increase financial burden. We investigated differences in LOS, discharge disposition, and charges between hospitalizations for serious infections in patients with and without OUD. We utilized the 2016 National Inpatient Sample—a nationally representative database of all discharges from US acute care hospitals. The population of interest was all hospitalizations for infective endocarditis, epidural abscess, septic arthritis, or osteomyelitis. The exposure was OUD, and the primary outcome was LOS until discharge, assessed by using a competing risks analysis to estimate adjusted hazard ratios (aHRs). Adjusted odds ratio (aOR) of discharge disposition and adjusted differences in hospital charges were also reported. Of 95,470 estimated hospitalizations for serious infections (infective endocarditis, epidural abscess, septic arthritis, and osteomyelitis), the mean age was 49 years and 35% were female. 46% had Medicare (government-based insurance coverage for people age 65+ years), and 70% were non-Hispanic white. After adjustment for potential confounders, OUD was associated with a lower probability of discharge at any given LOS (aHR 0.61; 95% CI 0.59–0.63; p < 0.001). OUD was also associated with lower odds of discharge to home (aOR 0.38; 95% CI 0.33–0.43; p < 0.001) and higher odds of discharge to a post-acute care facility (aOR 1.85; 95% CI 1.57–2.17; p < 0.001) or patient-directed discharge (also referred to as “discharge against medical advice”) (aOR 3.47; 95% CI 2.80–4.29; p < 0.001). There was no significant difference in average total hospital charges, though daily hospital charges were significantly lower for patients with OUD. Limitations include the potential for unmeasured confounders and the use of billing codes to identify cohorts. Our findings suggest that among hospitalizations for some serious infections, those involving patients with OUD were associated with longer LOS, higher odds of discharge to post-acute care facilities or patient-directed discharge, and similar total hospital charges, despite lower daily charges. These findings highlight opportunities to improve care for patients with OUD hospitalized with serious infections, and to reduce the growing associated costs.